Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
de decrease » we decrease (Expand Search), _ decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a de » _ de (Expand Search), a d (Expand Search), i de (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
de decrease » we decrease (Expand Search), _ decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a de » _ de (Expand Search), a d (Expand Search), i de (Expand Search)
-
2101
-
2102
-
2103
-
2104
-
2105
-
2106
-
2107
-
2108
Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>.
Published 2015“…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
-
2109
Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue.
Published 2017“…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C<sup>+</sup> and CD163<sup>+</sup> macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C<sup>+</sup>, CD163<sup>+</sup>: proinflammatory macrophage cell-surface markers.…”
-
2110
-
2111
-
2112
-
2113
-
2114
-
2115
-
2116
-
2117
-
2118
-
2119
-
2120